具有来自Phlogacanthus curviflorus的α-葡萄糖酶抑制活性的Ent-abietane二烯酸
Qian Wu1, Ren-Fen Ma1, Hua Zhang1
1School of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Phytochemistry
|December 24, 2025
概括
弗洛加坎图斯 (Phlogacanthus curviflorus) 产生了十四种新的四面体. 化D显示出对糖尿病点α-葡萄糖酶的强烈抑制,作为混合型抑制剂.
科学领域:
- 自然产品化学 自然产品化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 弗洛加坎图斯 (Phlogacanthus curviflorus) 是一种具有潜在药用功能的植物物种.
- 迪特尔类是一种具有多样化的生物活动的自然产品类.
- 抑制α-葡萄糖酶是治疗2型糖尿病的关键策略.
研究的目的:
- 从Phlogacanthus curviflorus中分离和表征新的ent-abietane diterpenoids. 这是一个非常重要的过程.
- 评估这些化合物对α-葡萄糖酶的抑制潜力.
- 阐明最强大的抑制剂的结合机制.
主要方法:
- 使用色谱技术分离化合物.
- 使用HR-ESIMS,NMR,ECD和X射线晶体学进行结构阐明.
- 酶抑制测定和结合模式分析.
主要成果:
- 确定了14种新的ent-abietane二甲 (curviflorinoids A-N) 类物质.
- 化D显示出显著的α-葡萄糖酶抑制活性 (IC50=2.70μM).
- 化D被描述为一种混合类型的抑制剂.
结论:
- 弗洛加坎图斯 (Phlogacanthus curviflorus) 是一种丰富的新型二类动物的来源.
- 曲化D代表了糖尿病治疗的有前途的化合物.
- 需要进一步研究这些迪特尔类药物的治疗潜力.
关键词:
在阿卡塔家族 (Acathaceae) 中.弗洛加坎图斯 (Phlogacanthus curviflorusus) 是一个曲的植物.ent-abietane 是一种二氧化的二氧化物.这是一种α-葡萄糖酶抑制剂.更多相关视频
09:21Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
11.1K
09:57Separation of Bioactive Small Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative Isoelectric Focusing IEF Method
Published on: June 14, 2020
10.0K
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
501
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
501
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
